Faron Pharmaceuticals Oy (GB:FARN) has released an update.
Faron Pharmaceuticals Oy has issued 333,333 warrants to the investment fund IPF Fund II, with a strike price of 1.50 euros and a seven-year exercise period, potentially increasing to a total of 750,000 warrants to reach a value of EUR 500,000. This move, integral to their capital financing strategy, comes as the company continues to develop innovative immunotherapies for cancer treatment, including their leading asset bexmarilimab, which is currently in clinical trials.
For further insights into GB:FARN stock, check out TipRanks’ Stock Analysis page.
